Table 2.
Summary of TEAEs (Safety Analysis Set)
| Patients, n (%) | Overall N=419 |
|---|---|
|
| |
| ≥1 TEAE | 221 (52.7) |
| ≥1 treatment-related TEAE | 66 (15.8) |
| ≥1 serious TEAE | 42 (10.0) |
| TEAE leading to study drug discontinuation | 25 (6.0) |
| TEAE leading to death | 6 (1.4) |
| TEAEs reported in ≥2% of patients | |
| Dyskinesia | 21 (5.0) |
| Fall | 21 (5.0) |
| Urinary tract infection | 21 (5.0) |
| Back pain | 15 (3.6) |
| Constipation | 11 (2.6) |
| COVID-19 | 10 (2.4) |
TEAE, treatment-emergent adverse event.